Exclusion of enrolled participants in randomised controlled trials: what to do with ineligible participants?

education & training (see medical education & training) paediatric thoracic medicine statistics & research methods

Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
02 12 2020
Historique:
entrez: 3 12 2020
pubmed: 4 12 2020
medline: 15 5 2021
Statut: epublish

Résumé

Post-randomisation exclusions in randomised controlled trials are common and may include participants identified as not meeting trial eligibility criteria after randomisation. We report how a decision might be reached and reported on, to include or exclude these participants. We illustrate using a motivating scenario from the BREATHE trial (Trial registration ClinicalTrials.gov, NCT02426112) evaluating azithromycin for the treatment of chronic lung disease in people aged 6-19 years with HIV in Zimbabwe and Malawi. Including all enrolled and randomised participants in the primary analysis of a trial ensures an unbiased estimate of the intervention effect using intention-to-treat principles, and minimises the effects of confounding through balanced allocation to trial arm. Ineligible participants are sometimes enrolled, due to measurement or human error. Of 347 participants enrolled into the BREATHE trial, 11 (3.2%) were subsequently found to be ineligible based on lung function criteria. We assumed no safety risk of azithromycin treatment; their inclusion in the trial and subsequent analysis of the intervention effect therefore mirrors clinical practice. Senior trial investigators considered diurnal variations in the measurement of lung function, advantages of retaining a higher sample size and advice from the Data Safety and Monitoring Board and Trial Steering Committee, and decided to include these participants in primary analysis. We planned and reported analyses including and excluding these participants, and in our case the interpretation of treatment effect was consistent. The decision, by senior investigators, on whether to exclude enrolled participants, should reflect issues of safety, treatment efficacy, statistical power and measurement error. As long as decisions are made prior to finalising the statistical analysis plan for the trial, the risk of exclusions creating bias should be minimal. The decision taken should be transparently reported and a sensitivity analysis can present the opposite decision.

Identifiants

pubmed: 33268410
pii: bmjopen-2020-039546
doi: 10.1136/bmjopen-2020-039546
pmc: PMC7713189
doi:

Banques de données

ClinicalTrials.gov
['NCT02426112']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e039546

Subventions

Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206316/Z/17/Z
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

BMJ. 2002 Sep 21;325(7365):652-4
pubmed: 12242181
J Clin Epidemiol. 2017 Apr;84:37-46
pubmed: 28088592
BMJ. 2009 Sep 07;339:b3244
pubmed: 19736281
JAMA. 1995 Feb 1;273(5):408-12
pubmed: 7823387
Trials. 2017 Dec 28;18(1):622
pubmed: 29282143
Clin Trials. 2015 Aug;12(4):418-23
pubmed: 26033877
Lancet. 2002 Mar 2;359(9308):781-5
pubmed: 11888606
BMJ. 2006 Apr 22;332(7547):969-71
pubmed: 16627519
BMJ. 2010 Jun 14;340:c2697
pubmed: 20547685
Trials. 2011 Feb 28;12:58
pubmed: 21356072
BMJ Evid Based Med. 2018 Jun;23(3):96-103
pubmed: 29678900
Rev Port Cardiol. 2002 Oct;21(10):1191-8
pubmed: 12522981
BMJ. 2015 May 27;350:h2445
pubmed: 26016488
J Fam Pract. 2002 Nov;51(11):969-71
pubmed: 12485553
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675

Auteurs

Andrea M Rehman (AM)

MRC International Statistics & Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK andrea.rehman@lshtm.ac.uk.

Rashida Ferrand (R)

Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.
Biomedical Research and Training Institute, Harare, Zimbabwe.

Elizabeth Allen (E)

Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.

Victoria Simms (V)

MRC International Statistics & Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.
Biomedical Research and Training Institute, Harare, Zimbabwe.

Grace McHugh (G)

Biomedical Research and Training Institute, Harare, Zimbabwe.

Helen Anne Weiss (HA)

MRC International Statistics & Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH